Ferrajoli Alessandra, O'Brien Susan M
Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston 77030-4009, USA.
Semin Oncol. 2004 Apr;31(2 Suppl 4):60-5. doi: 10.1053/j.seminoncol.2004.02.017.
Treatment options for patients with chronic lymphocytic leukemia have changed over the past two decades. This article reviews the experience accumulated with the use of alkylating agents alone and in combination; purine analogues alone and in combination and monoclonal antibodies such as rituximab, and alemtuzumab alone and in combination. The results obtained with different treatment strategies are summarized, compared, and reviewed.
在过去二十年中，慢性淋巴细胞白血病患者的治疗选择发生了变化。本文回顾了单独使用和联合使用烷化剂、单独使用和联合使用嘌呤类似物以及单独使用和联合使用利妥昔单抗、阿仑单抗等单克隆抗体所积累的经验。总结、比较并回顾了不同治疗策略所取得的结果。
